China’s NHC and NHSA Intensify Efforts to Stabilize Drug Supply and Prices Amid Shortages

The National Health Commission (NHC) has published a report titled “Recent Work on Securing Supply and Stabilizing Prices of Shortage Drugs,” outlining measures to enhance the oversight, analysis, and forecasting of drug supply and demand dynamics. The National Healthcare Security Administration (NHSA) is tasked with ongoing surveillance of drug prices and distribution, particularly for those on the national shortage drug list and the key monitoring list for clinically essential drugs prone to scarcity.

The NHC is directing regions to refine their reserve cooperation and mutual aid mechanisms for medical institutions, fostering information exchange and resource sharing. The Ministry of Industry and Information Technology is vigilant in tracking the production of scarce drug formulations and raw materials, enhancing central and local drug reserves, and working in tandem with the NHC to allocate national pharmaceutical reserves promptly, ensuring uninterrupted patient treatment.

The Ministry of Commerce is closely monitoring drug market dynamics and perpetuating market surveillance. The National Medical Products Administration is streamlining the review and approval processes for drugs on the national shortage list. The State Post Bureau is advancing the establishment of a comprehensive postal service platform, encouraging postal enterprises to expand medical delivery collaborations.

The State Administration for Market Regulation is maintaining its focus on antitrust enforcement and price supervision to protect competitive markets in the pharmaceutical sector and other essential industries. The NHSA has addressed the issue of certain drugs experiencing abnormal price surges, engaging in discussions with related companies to rectify excessive pricing. The State Administration of Taxation is conducting thorough inspections on high-risk tax enterprises in the pharmaceutical sector, identified through analysis and judgment, to crack down on tax-related illegalities, including the issuance of fraudulent value-added tax invoices by pharmaceutical companies.- Flcube.com

Fineline Info & Tech